Skip to Content

Belatacept Pregnancy and Breastfeeding Warnings

Belatacept is also known as: Nulojix

Medically reviewed on February 9, 2018

Belatacept Pregnancy Warnings

This drug is only recommended for use during pregnancy when there are no alternatives and the benefit outweighs the risk.

AU TGA pregnancy category: C
US FDA pregnancy category: C

-This drug crossed the placenta in animal studies.

Animal studies failed to demonstrate teratogenicity at doses approximately 16 to 19 times greater than the exposure associated with the maximum recommended human dose (MRHD). When administered daily during gestation, this drug was associated with maternal toxicity (infections) in a small percentage of study animals at doses approximately 3 times the MRHD exposure and an increased pup mortality (up to 100% pup mortality in some dams). In pups that survived, there were no abnormalities or malformations at doses up to 19 times the MRHD exposure. There are no controlled data in human pregnancy.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Belatacept Breastfeeding Warnings

No information is available on the use of this drug during breastfeeding. Because the half-life is 8 to 10 days, it may be more than a month after a dose before the drug is completely cleared from breastmilk.

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Data not available
Excreted into animal milk: Yes

-The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb, Princeton, NJ.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb, Princeton, NJ.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.